Cancer Care Ontario | Cancer Care Ontario

18 Results

Guidelines and Advice

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

Status: In-Review
ID: GL END 7-3
Version: 4

Apr 2020

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Status: Current
ID: 7-A-2018-2
Version: N/A

Jan 2020

Guidelines and Advice

Locoregional Management of In-Transit Metastasis in Melanoma

Status: Current
ID: GL 8-10
Version: N/A

Feb 2020

Guidelines and Advice

Regional Therapies for Colorectal Cancer Liver Metastases

Status: Current
ID: GL 2-30a
Version: N/A

Mar 2020

Guidelines and Advice

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Status: In-Review
ID: 3-22
Version: N/A

Apr 2020

Guidelines and Advice

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Status: Current
ID: GL 4-18
Version: N/A

Sep 2020

Guidelines and Advice

Best-Practice Guidance for Radiation Treatment Plan Physics Review

Status: Current

Apr 2020

Guidelines and Advice

Enhancing Clinical Cancer Genetic Service Delivery in Ontario - Recommendations for a New Model of Care

Status: Current
Version: 1.0

Dec 2020

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Mar 2025

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Guidelines and Advice

First-Line Therapy, Autologous Stem Cell Transplantation, and Post-Transplant Maintenance in the Management of Patients Newly Diagnosed with Mantle Cell Lymphoma

Status: In-Review
ID: RR SCT-9
Version: N/A

Jun 2020

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Status: Current
ID: PET 2024-1

Mar 2025

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Locoregional Management of In-Transit Metastasis in Melanoma

Regional Therapies for Colorectal Cancer Liver Metastases

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Best-Practice Guidance for Radiation Treatment Plan Physics Review

Enhancing Clinical Cancer Genetic Service Delivery in Ontario - Recommendations for a New Model of Care

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

First-Line Therapy, Autologous Stem Cell Transplantation, and Post-Transplant Maintenance in the Management of Patients Newly Diagnosed with Mantle Cell Lymphoma

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Pages